Company Overview and News

 
KLCI stays negative, falls 0.43%

2018-10-05 theedgemarkets
KUALA LUMPUR (Oct 5): The FBM KLCI remained in the negative zone at the midday break today, and fell 0.43% in line with the decline at regional markets.
UPBMF 5088 7113 5010 TPGVF 5202 2089 9334 6033 5199 9113 TGLVY 0143 5139 4588 PNADF 3867 0900 6888 AXXTF 2836 HIPEF PNAGF

 
KLCI falls 0.38% in tandem with regional retreat

2018-10-05 theedgemarkets
KUALA LUMPUR (Oct 5): The FBM KLCI fell 0.38% at mid-morning today, tracking fragile regional markets.
UPBMF 7113 TPGVF BATS 4162 2291 5202 2089 9334 6033 9113 4634 TGLVY 5139 PNADF 5226 3301 NDAQ 0900 6888 5819 AXXTF 1902 PNAGF

 
KLCI slips below 1,800 level as sellers outpace buyers

2018-09-27 theedgemarkets
KUALA LUMPUR (Sept 27): The FBM KLCI slipped back to below the 1,800-point level at midday break today, as sellers overtook buyers at the local bourse.
HLFBF 7113 7158 BATS TPGVF 4162 2089 5199 5347 7668 TNABY AXXTF 2836 HIPEF 1929 UPBMF 1082 6399 1163 5202 8311 2593 TGLVY 5139 0900 6888 TNABF 3719

 
KLCI erases earlier loss, crosses 1,800-level

2018-09-27 theedgemarkets
KUALA LUMPUR (Sept 27): The FBM KLCI erased its earlier losses and rose at mid-morning to cross the 1,800-point level.
5072 8621 7158 BATS 4162 7215 2089 5199 5347 3301 7668 TNABY AXXTF HIPEF PNAGF UPBMF 1163 5202 8311 6033 2593 5139 PNADF 0900 6888 TNABF 3719

 
KLCI falls 0.57% as China calls off trade talks with US

2018-09-24 theedgemarkets
KUALA LUMPUR (Sept 24): The FBM KLCI fell 0.57% at the midday breakin line with the tumble at most regional markets after China called off the trade talks with US officials.
APEXF 7090 UPBMF 5031 5202 2089 9334 6033 7123 5199 KLKBY 2445 PNADF 5347 3026 3867 0026 TNABY 5819 2836 1902 TNABF HIPEF PNAGF

 
KLCI slips 0.19% on mild profit taking

2018-09-24 theedgemarkets
KUALA LUMPUR (Sept 24): The FBM KLCI slipped at mid-morning and dipped 0.19% on some mild profit taking.
7052 7060 UPBMF 7036 5202 2089 6033 7123 5199 PNADF 3026 3867 0026 6645 5819 2836 1902 HIPEF PNAGF

 
FGV CEO Zakaria calls it quits

2018-09-19 theedgemarkets
KUALA LUMPUR: Less than a week after being suspended from work, Datuk Zakaria Arshad has thrown in the towel as group president and chief executive officer (CEO) of FGV Holdings Bhd, saying that he has had enough but also apologising for his mistakes.
5202 BSMAF 1818

 
KLCI seen rising on bargain hunting in line with global rally

2018-09-18 theedgemarkets
KUALA LUMPUR (Sept 19): The FBM KLCI is expected to trade range bound today and rise higher on some bargain hunting activities in line with the overnight gains at most global markets.
4863 7235 5196 MYTEF 5202 0162 3484

 
FGV, MSM, Ideal Jacobs, BFood, Vizione, WCT, Damansara Realty, YFG, TM, Superlon, MMAG and PanPages

2018-09-18 theedgemarkets
KUALA LUMPUR: Based on corporate announcements and news flow today, companies that may be in focus on Wednesday (Sept 19) may include the following: FGV Holdings Bhd, MSM Malaysia Holdings Bhd, Ideal Jacobs (M) Corp Bhd, Berjaya Food Bhd, Vizione Holdings Bhd, WCT Bhd, Damansara Realty Bhd, YFG Bhd, Telekom Malaysia Bhd, Superlon Holdings Bhd, MMAG Holdings Bhd and PanPages Bhd.
4863 7235 9679 5196 MYTEF 5041 5202 0162 BSMAF 7099 1818 3484

 
Suspended FGV CEO Zakaria resigns

2018-09-18 theedgemarkets
KUALA LUMPUR (Sept 18): FGV Holdings Bhd said today its group president and chief executive officer (CEO) Datuk Zakaria Arshad has resigned after being sent on compulsory leave on Sept 13.
5202 BSMAF 1818

 
Local retail sugar price among the world's lowest, say refiners

2018-08-28 theedgemarkets
KUALA LUMPUR (Aug 28): Local sugar refiners MSM Malaysia Holdings Bhd and Central Sugars Refinery Sdn Bhd (CSR) have pointed out that retail sugar price in Malaysia remains among the lowest in the world, ahead of the 10 sen per kg drop in the retail ceiling price of white sugar from Sept 1.
5202

 
Sugar price already low, say refiners

2018-08-28 malaymail
KUALA LUMPUR, Aug 28 — Sugar price in Malaysia is already among the lowest in the world even before a government-mandated reduction next month, said two refiners today.
5202

 
MSM’s export market expected to remain competitive

2018-08-28 theedgemarkets
MSM Malaysia Holdings Bhd (Aug 24, RM3.65) Downgrade to sell with a lower target price of RM3: MSM Malaysia Holdings Bhd’s first financial half ended June 30, 2018 (1HFY18) net profit of RM30.1 million (versus a net loss of RM56.1 million in 1HFY17) tracked behind estimates, accounting for 31% and 34% of our and consensus full-year estimates respectively.
5202

 
Sapura Energy, PUC, Axiata, Cahya Mata Sarawak, Magnum, Southern Steel, Dayang Enterprise, SKP Resources, MMC, MSM, Pos Malaysia, Paramount and Adventa

2018-08-24 theedgemarkets
KUALA LUMPUR (Aug 24): Based on corporate announcements and news flow today, companies that will be in focus on Monday (Aug 27) may include: Sapura Energy Bhd, PUC Bhd, Axiata Group Bhd, Cahya Mata Sarawak Bhd, Magnum Bhd, Southern Steel Bhd, Dayang Enterprise Holdings Bhd, SKP Resources Bhd, MMC Corp Bhd, MSM Malaysia Holdings Bhd, Pos Malaysia Bhd, Paramount Corp Bhd and Adventa Bhd.
4634 2852 5665 6888 IDEA 5141 ICLQY AXXTF 5202 532822 7155

 
MSM reports 2Q net profit on cheaper raw material, favourable forex

2018-08-24 theedgemarkets
KUALA LUMPUR (Aug 24): Sugar manufacturer MSM Malaysia Holdings Bhd reported a net profit of RM14.33 million in the second quarter ended June 30, 2018 (2QFY18) versus a RM21.45 million net loss a year earlier, due to lower raw material costs and favourable foreign exchange (forex) rates.
5202 BSMAF 1818

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...